Timing is Everything: Early Chemotherapy Boosts Colorectal Cancer Survival
Study finds starting chemotherapy within 6 weeks after colorectal cancer surgery improves survival rates.
118 articles
Timing is Everything: Early Chemotherapy Boosts Colorectal Cancer Survival
Study finds starting chemotherapy within 6 weeks after colorectal cancer surgery improves survival rates.
Extended Imatinib Therapy Slashes Recurrence Risk in High-Risk GIST Patients
Study shows 6 years of adjuvant imatinib significantly reduces relapse risk in high-risk GIST patients.
EMERALD-1 Trial: Immunotherapy Combo Boosts Survival in Liver Cancer
Adding durvalumab and bevacizumab to TACE improves progression-free survival in hepatocellular carcinoma.
High-Fiber Diet Trial Aims to Boost Immunotherapy Success in Melanoma Patients
New study explores how high-fiber diet affects gut microbiome and immune response in melanoma patients
Promising Results for Neoadjuvant Immunotherapy in Advanced Melanoma
Phase 1/2 trial shows high response rates for pembrolizumab-based neoadjuvant regimens in stage IIIB-D melanoma
DESTINY-Breast06 Trial: Trastuzumab Deruxtecan Shows Promise in HER2-Low Breast Cancer
Trastuzumab deruxtecan outperforms chemotherapy in HER2-low metastatic breast cancer clinical trial.
Breakthrough Combo Therapy Extends Survival in Aggressive Thyroid Cancer
Novel combination therapy shows promise for anaplastic thyroid carcinoma, significantly improving survival.
Shining Light on Relief: Photodynamic Therapy Shows Promise for Oral Mucositis in Cancer Patients
Study reveals photodynamic therapy's potential in reducing oral mucositis severity for cancer patients.
New Hope for BTK Inhibitor Intolerant Patients: Pirtobrutinib Shows Promise in B-Cell Malignancies
Pirtobrutinib demonstrates efficacy and tolerability in patients with B-cell cancers who couldn't tolerate other BTKis.
Immunotherapy Boost: New Hope for Early-Stage Lung Cancer Patients
Meta-analysis shows neoadjuvant immunotherapy plus chemo improves outcomes in resectable NSCLC patients.
Setback in Lung Cancer Trial: Immunotherapy-Radiation Combo Raises Concerns
Phase 2 trial of durvalumab with radiation for NSCLC halted early due to safety and efficacy issues.
Once-Every-3-Weeks Cisplatin Triumphs in Long-Term Head and Neck Cancer Study
Long-term analysis shows superior locoregional control with high-dose cisplatin in head and neck cancer.